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Airway responsiveness to hypertonic saline:
dose-response slope or PD15?
G. de Meer*, G.B. Marks#, J.C. de Jongste" and B. Brunekreef*
ABSTRACT: The result of airway challenge test with hypertonic saline (HS) is expressed as the
dose causing a 15% fall in forced expiratory volume in one second (FEV1; PD15). A noncensored
measure, such as the dose-response slope (DRS), allows the evaluation of the risk of asthma for
subjects with a fall in FEV1 ,15%. The aim of this study was to assess the relationship between
airway responsiveness to HS by PD15 or DRS, asthma symptoms and markers of eosinophilic
inflammation.
Data on current wheeze and airway responsiveness were obtained for 1,107 children (aged 8–
13 yrs). Blood eosinophils and serum eosinophil cationic protein (ECP) were assessed in subsets
(n5683 and 485). PD15 was assessed if FEV1 fell o15%, and the DRS was calculated for all tests.
Graphs were constructed to visualise relationships with current wheeze, blood eosinophils and
serum ECP. Odds ratios and Spearman’s correlation coefficients were calculated to quantify
these relationships.
Children with features of asthma had lower PD15 and higher DRS, and separation was most
pronounced for DRS. Prevalence of current wheeze increased continuously over the entire range
of DRS values. Blood eosinophils were significantly higher only for the highest values of DRS.
In conclusion, the continuous relationship between airway responsiveness and asthma
symptoms is in favour of a noncensored measure of airway responsiveness, such as the dose-
response slope.
KEYWORDS: Airway hyperresponsiveness, childhood asthma, dose-response slope, epidemiol-
ogy, hypertonic saline, provocative dose causing a 15% fall in forced expiratory volume in one
second
W
orldwide, airway challenge with hyper-
tonic saline (HS) is performed in child-
hood population studies that adhere to
the International Study on Allergy and Asthma in
Childhood (ISAAC) [1]. HS is an indirect stimu-
lus that causes bronchoconstriction, presumably
by the release of inflammatory mediators from
intermediary cells. There is evidence to suggest
that, in children with asthma, airway hyperre-
sponsiveness (AHR) to HS is more closely related
to the underlying airway inflammation than
AHR to direct stimuli, such as methacholine or
histamine [2, 3].
Conventionally, AHR to HS is considered to be
present if the forced expiratory volume in one
second (FEV1) falls by o15% fall after inhalation
of a provocative dose of f23 g HS (PD15 f23 g),
which is the cumulative dose after 15.5 min
inhalation at a minimal nebuliser output of
1.5 mL?min-1 [1]. According to this definition,
the presence of AHR to HS has a specificity of up
to 92% for asthma symptoms in the past 12
months and a doctor’s diagnosis of asthma [4].
In children with AHR, the PD15 provides a
measure of severity of airway hyperresponsive-
ness. However, PD15 can only be assessed in
individuals with AHR and will be of limited
value in general population studies in which the
prevalence of AHR is modest. It is not clear
whether subjects who have a sub-threshold (i.e.
,15%) fall in FEV1 have an increased probability
of asthma symptoms and pathology compared to
nonresponsive subjects. For methacholine and
histamine challenge test, attempts have been
made to develop a measure of airway respon-
siveness below the threshold of AHR [5–8], of
which the dose-response slope (DRS) that reflects
the fall in FEV1 per unit substance inhaled is
generally accepted. So far, no studies have been
published on the comparison of different mea-
sures of airway responsiveness using indirect
stimuli, such as HS.
In community populations, DRS to methacholine
or histamine is associated with asthma diagnosis
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and symptoms [8–14]. However, studies that compare the
discriminative power of DRS and provocative dose causing a
20% fall in FEV1 are scarce and have yielded conflicting results.
ABRAMSON et al. [9] found better separation of asthmatics and
nonasthmatics by DRS [9], whereas no difference was observed
by CHINN et al. [8]. However, protocols and prevalence of AHR
differed considerably for both studies, which may have
affected the results. Neither of these studies has evaluated
the relationship of DRS with symptoms below the threshold of
AHR separately. Therefore, it cannot be excluded that the
positive associations found in previous studies result from
strong relationships in the uppermost tail of DRS values. If so,
a continuous measure of airway responsiveness should be
avoided.
The aim of the present study was to evaluate DRS and PD15 as
measures of airway responsiveness to HS in a general
childhood population. Using graphical techniques, the rela-
tionship between DRS and asthma symptoms was examined.
The current authors were particularly interested to see whether
a cut-off point that marks a detectable rise in prevalence of
asthma symptoms for DRS could be determined. Similarly, the
relationship between DRS and markers of eosinophilic
inflammation, i.e. blood eosinophils and serum eosinophil
cationic protein (ECP), was evaluated.
METHODS
Study population and design
This study was part of a cross-sectional survey on the
respiratory health effects of living close to a freeway. A
detailed description of the study protocol has been published
previously [15]. Briefly, children of grades 4–8 (aged 8–13 yrs)
from 24 primary schools located within 400 m of a freeway
were invited to participate (south-western regions of The
Netherlands). All schools adhered to the Dutch public school
system, and may be regarded as a representative sample of
primary schools in The Netherlands. Parents completed the
ISAAC questionnaire on allergic and respiratory symptoms.
Children o8 yrs old were invited for skin-prick testing, airway
challenge with HS and blood withdrawal (immunoglobulin
(Ig)E, eosinophil counting). Serum ECP was assessed in a case-
control sample, in which cases were defined by the presence of
‘‘ever-wheeze’’, ‘‘ever-asthma’’ or ‘‘dry cough in the past 12
months’’. For each case, two control children were chosen
without any of the previously outlined symptoms. The parents
gave informed consent for each test separately. The Medical
Ethical Board of the University of Wageningen, Wageningen,
The Netherlands, approved the study protocol.
For the current analyses, children aged o8 yrs (n52,207) were
included, in whom data were obtained for the presence of
wheeze in the past 12 months (n52,159) and for the completion
of the bronchial challenge test (n51,107). Blood eosinophil
counting occurred in 682 of these children. Serum ECP was
assessed in 485 children of whom 34% were cases as defined
previously, which was similar to the number of cases in
children without ECP assessment (32%) and can therefore be
regarded a representative sample.
Questionnaire
The ISAAC core questionnaire was completed by one of the
parents or carers. For the current study, ‘‘current wheeze’’ was
defined as if a child had a history of wheeze in the past 12
months, and ‘‘ever-asthma’’ was defined as if parents
confirmed a history of asthma.
Blood eosinophils and serum eosinophil cationic protein
Blood eosinophils were determined by Coulter counter auto-
analyser (AML, Anvers, Belgium) and expressed as the
number of cells per L.
Serum ECP was determined by fluoro-immunoassay, by the
same lab that performed IgE analyses (Pharmacia, Woerden,
The Netherlands). Blood and serum handling occurred
according to the test manufacturer’s protocol.
Hypertonic saline challenge
Airway challenge with HS (4.5%) was performed according to
the protocol approved by the ISAAC steering committee [3].
Salbutamol was withheld 6 h before the airway challenge test,
and antihistaminics and cromoglycate at 48 h. Baseline lung
function was assessed according to European Respiratory
Society guidelines, using a pneumotachometer (Jaeger,
Wu¨rzburg, Germany). Informed consent for the airway
challenge test was obtained for 1,379 children who completed
questionnaire data. A total of 146 children were excluded,
because of inability to perform satisfactory forced spirometry
manoeuvres (n5130), or a baseline FEV1 ,75% of the
predicted value according to ZAPLETAL et al. [16] (n516).
Another 126 tests were discarded because of excessive cough,
unwillingness or inability to perform acceptable spiromety.
The protocol comprised of inhalation of 4.5% HS aerosol
generated by an ultrasonic nebuliser closed system (Jaeger), for
0.5, 1, 2, 4 and 8 min (total: 15.5 min). During the study period,
nebuliser output did not fall below 1.5 mL?min-1, which is the
minimal level, according to the ISAAC protocol [3]. After each
dose step, two reproducible measurements of FEV1 were
assessed, of which the higher was selected. If FEV1 fell 10–15%
compared with pre-challenge FEV1, the same dose step was
repeated. The test stopped after a total inhalation time of
15.5 min, or if FEV1 fell o15%. Salbutamol was administered
to relieve airflow limitation or symptoms when needed. The
amount of inhaled HS was assessed by the difference in
canister weight prior to and after the test. PD15 was calculated
by linear interpolation between the last two points of the dose
response curve where FEV1 fell o15%. AHR was defined by a
PD15 f23.0 g. The DRS was assessed for all tests by dividing
the % fall in FEV1 from pre-challenge FEV1 by the amount of
HS inhaled [5].
Statistical analysis
Graphs were constructed to visualise the relationships between
DRS and current wheeze, blood eosinophils or serum ECP.
DRS values were stratified according to the % fall in FEV1. For
each stratum, the prevalence rate and odds ratios (OR) with
95% confidence intervals of current wheeze were assessed.
Differences in PD15 and DRS between children with and
without current wheeze and ever-asthma, respectively, were
assessed by t-test. Prior, DRS values were log transformed to
normalise residuals. A constant of 1.0 was added to all DRS
values to eliminate negative values that occurred if lung
function improved during the challenge test. Discriminatory
capacities of DRS and PD15 for ever-asthma and current
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wheeze were assessed by dividing the mean difference by the
standard deviation [17].
Since no assumptions were made on the normality of the
distribution and linearity of the relationship between the
parameters, Spearman’s correlation coefficients were calcu-
lated as correlation measures for the relationships between
DRS, blood eosinophils and serum ECP.
RESULTS
The study population comprised 1,107 children with complete
data on current wheeze and airway challenge. Blood eosino-
phils were assessed in 682 and serum ECP in 485 children.
There was no difference in sex, paternal asthma, passive
smoking, diagnosed asthma and current wheeze between
children with and without data for airway responsiveness,
blood eosinophil counting or serum ECP. Table 1 shows the
characteristics of the study population. In 32 children (3%),
the predicted value for FEV1 exceeded 120% [16]. During the
challenge test, FEV1 increased in 30 children ranging 0.2–
14.9%, and increased .5% in six children.
Figure 1 shows the relationship between levels of DRS and
current wheeze. The prevalence of wheeze increases with
increasing DRS values (fig. 1a). This also exists for DRS values
below the threshold of AHR. Similarly, there is a linear
increase in OR of current wheeze with increasing levels of DRS
(fig. 1b). Both indices of airway responsiveness discriminated
between children with and without asthma features, i.e.
current wheeze and ever-asthma (tables 2 and 3). The
discriminatory capacity, as indicated by the mean difference
divided by the standard deviance, was higher for log DRS than
for PD15.
Figure 2 shows the relationship between DRS and blood
eosinophilic markers, stratified for the presence of current
wheeze. Both blood eosinophils (fig. 2a) and serum ECP
(fig. 2b) were higher in symptomatic children. The figures
suggest a relationship only for the highest values of DRS that
exceeded the threshold value for AHR. Spearman’s correlation
coefficients confirmed no relationship below the threshold of
AHR, and a statistically significant correlation for blood
eosinophils in children with AHR and current wheeze
(table 4). Corticosteroid treatment aims to reduce inflamma-
tion and may, therefore, affect the results. After exclusion of
TABLE 1 Characteristics of the study population of 1,107
children
Characteristics
Mean age yrs 10 (8–13)
Females 534 (48)
Current wheeze 194 (18)
Ever-asthma# 91 (8)
Inhaled corticosteroid treatment 42 (4)
Mean FEV1 100 (75–168)
AHR 225 (20)
Geometric mean DRS 0.70 (-0.80–14.30)
Median blood eosinophils 6106?L-1" 210 (1–2190)
Median serum ECP+ 5.9 (2.0–201.0)
Data are presented as mean (range), n (%) and median (range). FEV1: forced
expiratory volume in one second; AHR: airway hyperresponsiveness; DRS:






































FIGURE 1. The relationship between levels of dose-response slope (DRS) and
current wheeze given by a) prevalence rate of current wheeze per stratum of DRS
and b) odds ratios (OR) for current wheeze and 95% confidence intervals per
stratum of DRS. The strata for DRS are defined by a fall in forced expiratory volume
in one second of f5%, 5–7.5%, 7.5–10%, 10–15%, 15–25%, 25–45% and 45–70%.
……: threshold of airway hyperresponsiveness (AHR). #: below the AHR threshold;
": above the AHR threshold; +: median DRS per stratum.
TABLE 2 Dose-response slope (DRS) and PD15 in children






n Mean n Mean
Log DRS 194 1.41 913 0.55 ,0.001 0.63
PD15 77 0.79 148 0.94 ,0.001 0.48
PD15: provocative dose causing a 15% fall in forced expiratory volume in one
second; D/SD: mean difference divided by the standard deviation.
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these children, the correlation coefficient for blood eosinophils
in symptomatic children increased (r50.34; p50.03).
DISCUSSION
This large-scale, population-based sample of school children
aged 8–13 yrs demonstrates a continuous increase in the risk of
current wheeze with increasing airway responsiveness to HS,
even below the threshold of AHR. This result supports the use
of a continuous measure, such as the DRS, to express the
results of bronchial challenge testing.
In this study population, no arguments for selection bias were
found, since prevalence rates of asthma features and general
characteristics were similar among children who participated
in bronchial challenge testing and those who did not.
Nevertheless, selection cannot be completely ruled out, since
no information was collected for children without question-
naire data.
Airway responsiveness was higher in children with asthma
features, both for DRS and PD15, although discrimination was
highest for DRS. The DRS allows the assessment of airway
responsiveness for all individuals, including those who do not
reach the threshold of AHR. It was hypothesised that this would
be an advantage if there was a relationship with asthma features
at levels of DRS below AHR. In this population, it has been clearly
shown that the risk of asthma symptoms increased over the
whole range of DRS values, including those below the threshold
of AHR. To the current authors’ knowledge, this is the first study
in which separate analyses were performed for both sides of the
threshold defining AHR. Previous studies found higher values
for DRS in subjects with asthma features, but did not evaluate
subjects without AHR separately [8, 9]. Hence, the positive
association between asthma symptoms and DRS may have
occurred predominantly in subjects with AHR who will have
highest DRS values.
Another method to obtain results of airway challenge testing
for all individuals is censoring PD15 to a fixed value in subjects
without AHR. This procedure, however, limits statistical
analyses due to its extreme, skewed distribution. Expressing
the results of bronchial challenge test with HS by a
dichotomous variable, such as AHR, or by a censored measure,
such as PD15, does not address the continuous relationship
between asthma features and airway responsiveness without a
threshold, as observed in this study population.
TABLE 3 Dose-response slope (DRS) and PD15 in children
with and without ever-asthma
Ever-asthma No ever-asthma p-value D/SD
n Mean n Mean
Log DRS 91 1.54 1004 0.63 ,0.001 0.65
PD15 39 7.27 186 10.38 0.003 0.52
PD15: provocative dose causing a 15% fall in forced expiratory volume in one
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FIGURE 2. Inflammatory markers (a) blood eosinophils and b) serum eosinophil
cationic protein (ECP)) by dose-response slope (DRS) in children with (&) and without
(h) current wheeze. Data are presented as the geometric mean and 95% confidence
interval per stratum of DRS. The strata for DRS are defined by a fall in forced expiratory
volume in one second off5%, 5–7.5%, 7.5–10%, 10–15%, 15–25%, 25–45% and 45–
70%. ……: threshold of airway hyperresponsiveness (AHR). #: below the AHR
threshold; ": above the AHR threshold; +: median DRS per stratum.
TABLE 4 Spearman’s correlation coefficients (r) for dose-
response slope, blood eosinophils, and serum
eosinophil cationic protein (ECP) by airway
hyperresponsiveness (AHR) and current wheeze
Without AHR With AHR
n r n r
Blood eosinophils
All children 537 0.03 145 0.22**
No current wheeze 460 0.03 89 0.11
Current wheeze 77 0.03 56 0.26*
Serum ECP
All children 379 -0.01 106 0.10
No current wheeze 328 -0.01 67 0.10
Current wheeze 51 -0.02 39 0.03
*: p,0.05; **: p,0.01.
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Airway responsiveness above the threshold of AHR has
been found repeatedly to increase the risk of developing asthma
[18–22]. Although it has been shown that there is a higher risk of
current wheeze in children with low levels of airway respon-
siveness in this cross-sectional survey, the predictive value of low
levels of airway responsiveness for the future development of
asthma needs to be confirmed in follow-up studies.
An attempt was made to study the relationship between
airway responsiveness and eosinophilic inflammation by
including analyses on blood eosinophils and serum ECP. A
positive correlation was observed between blood eosinophils
and airway responsiveness, though only if airway responsive-
ness exceeded the threshold of AHR.
The relationship between DRS and asthma symptoms below the
threshold of AHR was not accompanied by a similar relationship
of DRS in this range with blood eosinophilic markers. This
discrepancy may be due to differences in the time course of these
variables. While symptoms refer to a period of the past 12
months, eosinophilic markers presumably reflect a shorter
period of time. Since airway responsiveness below the level of
AHR was only associated with asthma symptoms, it is suggested
that airway responsiveness to hypertonic saline also reflects
longer-term airway abnormalities. Other explanations may be a
lack of sensitivity for blood eosinophilic markers to detect
bronchial inflammation [23], or the possibility that airway
responsiveness and eosinophilic activation represent different
inflammatory pathways [24, 25].
In summary, a positive association between the risk of asthma
symptoms and airway responsiveness to hypertonic saline was
found, even below the threshold of airway hyperresponsive-
ness. Blood eosinophils and serum eosinophil cationic protein
were only increased at the higher end of the dose-response
slope spectrum. In conclusion, in general population studies,
the dose-response slope should be preferred to threshold
measures, such as provocative dose causing a 15% fall in
forced expiratory volume in one second, to express airway
responsiveness. It allows the assessment of airway responsive-
ness over the entire range, both as determinant and end point.
Including all test results increases statistical power, which may
benefit study efficacy.
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